Products

Data

Feature

Request Demo

Last update 08 May 2025

CLEC9A

Last update 08 May 2025

Basic Info

Synonyms

C-type lectin domain containing 9A, C-type lectin domain family 9 member A, CD370

+ [4]

Introduction

Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.

Drugs associated with CLEC9A

Anti-CLEC9A antibody(Monash University/University of Queensland)

Target

CLEC9A

Mechanism

CLEC9A modulators

Active Org.

The University of Queensland [+1]

Originator Org.

The University of Queensland [+1]

Active Indication

Infectious Diseases [+2]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CLEC9A

100 Translational Medicine associated with CLEC9A

0 Patents (Medical) associated with CLEC9A

208

Literatures (Medical) associated with CLEC9A

01 Apr 2025·Experimental Hematology

Methodologic considerations on how to identify human hematopoietic stem cells

Article

Author: Anjos-Afonso, Fernando ; Bonnet, Dominique ; Hinchly, Taylor

Recently, human CD34⁺ hematopoietic stem cells (HSCs) have been purified to a frequency of approximately one in three cells, a population denoted as CD34⁺CD38^-CD45RA^-CD90^+/- endothelial protein C receptor (EPCR)⁺ HSCs. This work aimed to evaluate the methodology for CD34⁺ HSC isolation, exploring differences in antibody clones, conjugates, source of cells, and additional cell surface antigens (integrin-α6, CLEC9A, and GPRC5C) to enhance the purity of these EPCR⁺ HSCs. We are emphasizing here the importance of experimental planning and antibody panel selection concerning the isolation of these human HSCs from multiple sources and providing important notes on the pitfalls of the reagents used for such purposes. Our results should enable a better reproducibility of results between laboratory tests as well as further pursuits of work toward improving the enrichment of human HSCs.

01 Apr 2025·International Journal of Biological Macromolecules

Single-cell transcriptional footprint for pseudogene SsCLEC9A is associated with antigen processing and presentation in Sus scrofa

Article

Author: Wang, Hao ; Chan, Shuheng ; Zhang, Liguo ; Zha, Chengwan ; Yu, Runjie ; Fang, Meiying ; Jia, Shangang ; Luo, Yabiao ; Xie, Fuyin ; Wang, Yubei ; Xue, Pengxiang ; Xue, Mingming ; Yang, Xiaoyang ; Yang, Lixian ; Yang, Shaojun ; Huang, Ning ; Lan, Yezhi

The C-type lectin domain family 9 member A (CLEC9A) is widely recognized as the most critical receptor protein for cross presentation of dead cell associated antigens in animal dendritic cells (DCs). Surprisingly, we revealed for the first time that the sole CLEC9A (SsCLEC9A) in pigs becomes a pseudogene due to three causal mutations that occurred approximately 29.8-44.7 million years ago, challenging the significance of CLEC9A in immune cross-presentation across mammals. Interestingly, we found that SsCLEC9A can transcribe a mutated transcript encoding a truncated protein. Through fluorescence-activated cell sorting and single-cell RNA sequencing, we observed that SsCLEC9A mutant transcript is mainly expressed in DCs and correlated with the expression of its homolog CLEC7A. Further data showed that DCs with SsCLEC9A mutant transcripts exhibited reduced cellular interaction ability and downregulation of antigen presentation function, displaying the characteristics of mature DCs. In addition, introducing the conserved sequence of CLEC9A gene into FLT3L-induced bone marrow hematopoietic cells significantly increased the expression of genes involved in antigen processing and presentation. This study presents a natural mutation model of pseudogenes to understand its transcriptional adation, and provides a fundamental basis for rescuing SsCLEC9A to promote immunity in pigs in the future.

01 Feb 2025·Cell Reports

MAIT cells protect against sterile lung injury

Article

Author: Lason, Wojciech ; Hinks, Timothy S C ; Zhang, Xiawei ; Li, Shuailin ; Greco, Maria ; Klenerman, Paul

Mucosal-associated invariant T (MAIT) cells, the most abundant unconventional T cells in the lung, can exhibit a wide range of functional responses to different triggers via their T cell receptor (TCR) and/or cytokines. Their role, especially in sterile lung injury, is unknown. Using single-cell RNA sequencing (scRNA-seq), spectral analysis, and adoptive transfer in a bleomycin-induced sterile lung injury, we found that bleomycin activates murine pulmonary MAIT cells and is associated with a protective role against bleomycin-induced lung injury. MAIT cells drive the accumulation of type 1 conventional dendritic cells (cDC1s), limiting tissue damage in a DNGR-1-dependent manner. Human scRNA-seq data revealed that MAIT cells were activated, with increased cDC populations in idiopathic pulmonary fibrosis patients. Thus, MAIT cells enhance defense against sterile lung injury by fostering cDC1-driven anti-fibrotic pathways.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us: phs@patsnap.com

What we do

Drug
Clinical Progress
Patent
Literature
Report
News

CLEC9A

Basic Info

Related

Analysis